First Manhattan’s KalVista Pharmaceuticals KALV Stock Holding History

First Manhattan’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-392,504	Closed	-$3.78M	–	1507
2023 Q3	$3.78M	Hold	392,504	–	–	0.01%	246
2023 Q2	$3.53M	Buy	392,504 +122,900	+46%	+$1.13M	0.01%	247
2023 Q1	$2.12M	Buy	+269,604	New	+$2.01M	0.01%	313

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

First Manhattan's KALV Position: Q4 2023 in Review

First Manhattan sold out of KalVista Pharmaceuticals (KALV) in Q4 2023, closing a stake of 392,504 shares — an estimated $3.78M sold.

First Manhattan first reported a position in KALV in Q1 2023 and held it in 3 quarters. The position peaked at $3.78M in Q3 2023. 93 funds tracked by Wall St. Rank hold KALV as of Q4 2023.

First Manhattan reported no remaining KalVista Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 392,504 KalVista Pharmaceuticals shares in Q4 2023, an estimated $3.78M.
First Manhattan first reported a position in KalVista Pharmaceuticals in Q1 2023 and held it in 3 quarters.
First Manhattan's KalVista Pharmaceuticals position peaked at $3.78M in Q3 2023.
93 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.